Clinical trial
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
Active, not recruiting · Phase 2 · 1 countries · Registry ID NCT07017179
What this study is about
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
Basic eligibility
Full registry criteria
Treatments and study arms
AZD6234
Participants will receive a subcutaneous injection weekly
Placebo
Participants will receive a subcutaneous injection weekly.
AZD9550
Participants will receive a subcutaneous injection weekly
Plocebo
Participants will receive a subcutaneous injection weekly
AZD6234 in combination with AZD9550
Participants will receive a subcutaneous injection weekly
Placebo
Participants will receive a subcutaneous injection weekly
Primary outcomes
To assess the safety and tolerability of repeated subcutaneous(SC) doses of AZD6234 compared to placebo.
To assess the safety and tolerability of repeated SC doses of AZD9550 and AZD6234 in combination with AZD9550 compared to placebo.